The pathology of intermediate-risk non-muscle-invasive bladder cancer is less well-defined than both high-risk and low-risk presentations of this disease. Recently reported guidelines seek to aid clinicians in classification of intermediate-risk patients, and also provide treatment recommendations for this subgroup.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lamm, D. L. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent, TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163, 1124–1129 (2000).
Sylvester, R. J., Oosterlinck, W. & van der Meijden, A. P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol. 171, 2186–2190 (2004).
Hall, M. C. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 178, 2314–2330 (2007).
Brausi, M. et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J. Urol. 186, 2158–2167 (2011).
Shariat, S. F., Chade, D. C., Karakiewicz, P. I., Scherr, D. S. & Dalbagni, G. Update on intravesival agents for non-muscle invasive bladder cancer. Immunotherapy 2, 381–392 (2010).
Kamat, A. M., Witjes, J. A. & Brausi, M. Defining and treating the spectrum of intermediate-risk NMIBC. J. Urol. http://dx.doi.org/10.1016/j.juro.2014.02.2573.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014).
Di Stasi, S. M. et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomized controlled trial. Lancet Oncol. 12, 871–879 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Malkowicz, S. Defining intermediate-risk non-muscle-invasive bladder cancer. Nat Rev Urol 11, 430–432 (2014). https://doi.org/10.1038/nrurol.2014.172
Published:
Issue date:
DOI: https://doi.org/10.1038/nrurol.2014.172
